Potassium heptafluorobutyrate | 2966-54-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: Potassium heptafluorobutyrate
• 英文别名: heptafluorobutyric acid; potassium salt；potassium;2,2,3,3,4,4,4-heptafluorobutanoate
• CAS: 2966-54-3
• 化学式: C₄F₇O₂*K
• 分子量: 252.13
• InChiKey: UDYXGZXUMUTLSW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.43
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  9

安全信息

• 海关编码：
  2915900090

反应信息

• 作为反应物：
  描述：

  Potassium heptafluorobutyrate 在 dipotassium peroxodisulfate 作用下， 以 水 为溶剂， 反应 0.75h， 以62.5%的产率得到全氟己烷
  参考文献：
  名称：

  Serguchev, Yu. A.; Davydova, V. G., Journal of Organic Chemistry USSR (English Translation), 1982, vol. 18, p. 2303 - 2304

  摘要：

  DOI：
• 作为产物：
  描述：

  七氟丁腈 在 氢氧化钾 作用下， 生成 Potassium heptafluorobutyrate
  参考文献：
  名称：

  Haszeldine, R. N., Journal of the Chemical Society

  摘要：

  DOI：

文献信息

• Benzopyran derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05874446A1

  公开（公告）日：1999-02-23

  Novel benzopyran and benzoxazine derivatives represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 represent a lower haloalkyl group, R.sub.3 represents a hydrogen atom, etc., R.sub.4 represents a heterocyclic group or A--O-- wherein A represents a cyclic structure, etc., R.sub.5 and R.sub.6 represent a lower haloalkyl, X represents .dbd.N--, N.fwdarw.O, etc, are disclosed. These compounds exhibit K.sup.+ channel opening activating and can be widely used as an anti-asthma drug, an anti-epilepsy drug, etc.

  新型苯并吡喃和苯并噁嗪衍生物的一般公式表示为：##STR1##其中R.sub.1和R.sub.2代表较低的卤代烷基，R.sub.3代表氢原子，等等，R.sub.4代表杂环基或A--O--，其中A代表环状结构，等等，R.sub.5和R.sub.6代表较低的卤代烷基，X代表.dbd.N--，N.fwdarw.O等。这些化合物表现出K.sup.+通道开放激活作用，可广泛用作抗哮喘药物、抗癫痫药物等。
• Nucleophilic perfluoroalkylation of diaryldisulfides with perfluorocarboxylate salts
  作者：Nicolas Roques

  DOI：10.1016/s0022-1139(00)00374-2

  日期：2001.2

  A new industrial and economical route to trifluoromethyl aryl sufides by thermal decarboxylation of trifluoroacetate salts has been recently developed. The possibility of generalising this reaction of “trifluorodecarboxylation” to RfCO2K (Rf: CCl3, CF2Cl, CF3CF2, CF3CF2CF2) in order to synthesise RfSAr has been studied. Thus, the reaction was effective with RfCO2K (Rf=CCl3, CF3CF2) and a new route

  最近已经开发了通过三氟乙酸盐的热脱羧制备三氟甲基芳基硫化物的新的工业和经济途径。为了合成R f SAr，已经研究了将“三氟脱羧”反应合成为R f CO 2 K（R f：CCl 3，CF 2 Cl，CF 3 CF 2，CF 3 CF 2 CF 2）的可能性。因此，该反应在R f CO 2 K（R f = CCl 3，CF 3 CF 2），并简要举例说明了制备芳基五氟乙基硫化物CF 3 CF 2 SAr的新途径。
• Remedies for peripheral circulation disturbances
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US06248777B1

  公开（公告）日：2001-06-19

  It is an object of the present invention to provide novel therapeutic agents for peripheral vascular disease. The present invention provides pharmaceutical compositions comprising a benzopyran or benzoxazine derivative of the general formula (1): wherein; R1 represents a hydrogen atom, a lower alkyl group or an aryl group, or R1 directly couples with Q or R11 to form a single bond; R2represents a substituted or unsubstituted amino group, a saturated or unsaturated heterocyclic group, A—O—or —C(═X)Y; Q represents ═N—, N+—O−or C(R11)R12; R3 and R4 each represent a hydrogen atom, a lower alkyl group or a substituted lower alkyl group having a halogen atom or a lower alkoxy group as a substituent or the like; and R5 and R6 each represent a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group or the like; and a pharmaceutically acceptable carrier.

  本发明的目的是提供新型的周围血管疾病治疗剂。本发明提供了一种含有苯并吡喃或苯并噁嗪衍生物的药物组合物，其通式为（1）：其中，R1代表氢原子、低碳基或芳基，或R1直接与Q或R11结合形成单键；R2代表取代或未取代的氨基、饱和或不饱和的杂环基、A—O—或—C(═X)Y；Q代表═N—、N+—O−或C(R11)R12；R3和R4各自代表氢原子、低碳基或带有卤原子或低烷氧基等取代基的取代低碳基；R5和R6各自代表氢原子、卤原子、低碳基、低卤基烷基或类似物；以及药学上可接受的载体。
• Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: F: PerFHalOrg.9, 7, page 50 - 101
  作者：

  DOI：——

  日期：——
• 6-Substituted 2,2-Bis(fluoromethyl)-benzopyran-4-carboxamide K + channel openers
  作者：Naoki Taka、Hiroshi Koga、Haruhiko Sato、Takenori Ishizawa、Tadakatsu Takahashi、Jun-ichi Imagawa

  DOI：10.1016/s0968-0896(00)00064-x

  日期：2000.6

  In the course of our study to find an ideal antihypertensive potassium channel opener (KCO), N-(2-cyanoethyl)-2,2 bis(fluoromethyl)-6-pentafluoroethyl-2H-1-benzopyran-4-carboxamide (13f, KC-515) showed a highly potent, slow and long-lasting antihypertensive effect with reduced reflex tachycardia, together with the beneficial effects of KCO such as improvement in lipid metabolism. These profiles identify KC-515 as a potential candidate. In conscious spontaneously hypertensive rats (SHR), the onset of the hypotensive effect of KC-515 (13f) was gradual and the maximum response was attained at around 6 h after dosing. The duration of action was over 18 h for 0.1 mg/kg. When administered to Zucker rats for 2 weeks with 0.03-0.3 mg/kg po range in the antihypertensive doses in hypertensive rat models, KC-515 (13f) significantly and dose-dependently reduced serum triglycerides to less than 70% of control without affecting total cholesterol. (C) 2000 Elsevier Science Ltd. All rights reserved.